Results 301 to 310 of about 128,988 (349)
Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. [PDF]
BMJ Open GastroenterolBrusselaers N +3 more
europepmc +1 more source
Proton Pump Inhibitors and CKD: The Evidence Builds.
J Am Soc NephrolGrams ME, Wilson FP.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Deprescribing proton pump inhibitors
Australian Journal of General Practice, 2022Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P. +3 more
openaire +4 more sources
Proton pump inhibitors and osteoporosis
Current Opinion in Rheumatology, 2016Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard +2 more
openaire +3 more sources
Hypomagnesemia and proton-pump inhibitors
Expert Opinion on Drug Safety, 2013Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia.We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from ...
Laura Gasbarrone +2 more
openaire +3 more sources
Pharmacogenomics of proton pump inhibitors
Pharmacogenomics, 2004Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Naohito Shirai +4 more
openaire +3 more sources
Esomeprazole: a proton pump inhibitor
Expert Review of Gastroenterology & Hepatology, 2009Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Vic Velanovich +2 more
openaire +3 more sources